Management controversies in Barrett's oesophagus

Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 195-205

  Max Almond, L ^a   Barr, Hugh ^a  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

Ablation; Barrett's oesophagus; Dysplasia; Endoscopic resection; Intramucosal cancer

Indexed keywords

ABLATION THERAPY; BARRETT ESOPHAGUS; BIOLOGICAL THERAPY; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CRYOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; ELECTROCOAGULATION; ENDOSCOPIC SURGERY; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; ESOPHAGUS DYSPLASIA; ESOPHAGUS RESECTION; FOCAL INTRAMUCOSAL CARCINOMA; HUMAN; LASER SURGERY; PATIENT CARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADICAL ENDOTHERAPY; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TIME TO TREATMENT; TUMOR INVASION;

ABLATION TECHNIQUES; ADENOCARCINOMA; BARRETT ESOPHAGUS; CARCINOMA IN SITU; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; HUMANS; MUCOUS MEMBRANE; PRECANCEROUS CONDITIONS; WATCHFUL WAITING;

EID: 84896691780     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0816-z     Document Type: Review

References (118)

1. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344(8936):1533-6.
2. Caygill CP, Watson A, Reed PI, et al. UK National Barrett's Oesophagus Registry (UKBOR) and the 27 Participating Centres. Characteristics and regional variations of patients with Barrett's oesophagus in the UK. Eur J Gastroenterol Hepatol. 2003;15(11):1217-22.
3. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825-31.
4. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a delphi process. Gastroenterology. 2012;143:336-46.
5. Fitzgerald RC, Rubenstein JH. Oracular guidance on clinical management of early neoplastic Barrett's esophagus. Gastroenterology. 2012;143(2):282-4.
6. Yachimski P, Nishioka NS, Richards E, et al. Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy. Clin Gastroenterol Hepatol. 2008;6(11):1206-11.
7. Caygill CP, Royston C, Charlett A, et al. Mortality in Barrett's esophagus: three decades of experience at a single center. Endoscopy. 2012;44(10):892-8.
8. Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther. 2008;27(4):316-20.
9. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049-57.
10. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365(15):1375-83.
11. Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8(3):235-44 quiz e32.
12. Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237-49.
13. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg. 1988;75(8):760-3.
14. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut. 1991;32(12):1441-6.
15. Iftikhar SY, James PD, Steele RJ, et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut. 1992;33(9):1155-8.
16. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett's cancer. Gut. 1996;39(4):574-9.
17. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92(2):212-5.
18. Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol. 1998;93(4):536-41.
19. Hage M, Siersema PD, van Dekken H, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol. 2004;39(12):1175-9.
20. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2012;61(7):970-6.
21. Almond LM, Barr H, Jankowski J. Barrett's Oesophagus. In: SM Griffin, SA Raimes, editors. A companion to specialist surgical practice: oesophagogastric surgery. 5th ed. Saunders Elsevier (in print).
22. Das D, Ishaq S, Harrison R, et al. Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol. 2008;103(5):1079-89.
23. Cook MB, Wild CP, Everett SM, et al. Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2007;16(10):2090-6.
24. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523-30.
25. Sikkema M, Looman CW, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol. 2011;106(7):1231-8.
26. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120(7):1630-9.
27. Altorki NK, Sunagawa M, Little AG, et al. High-grade dysplasia in the columnar-lined esophagus. Am J Surg. 1991;161(1):97-9.
28. Pera M, Trastek VF, Carpenter HA, et al. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg. 1992;54(2):199-204.
29. Streitz JM Jr, Andrews CW Jr, Ellis FH. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg. 1993;105(3):383-7.
30. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology. 1993;105(1):40-50.
31. Edwards MJ, Gable DR, Lentsch AB, et al. The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann Surg. 1996;223(5):585-9.
32. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108(5):813-21.
33. Rice TW, Falk GW, Achkar E, et al. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol. 1993;88(11):1832-6.
34. Collard JM, Romagnoli R, Hermans BP, et al. Radical esophageal resection for adenocarcinoma arising in Barrett's esophagus. Am J Surg. 1997;174(3):307-11.
35. Ferguson MK, Naunheim KS. Resection for Barrett's mucosa with high-grade dysplasia: implications for prophylactic photodynamic therapy. J Thorac Cardiovasc Surg. 1997;114(5):824-9.
36. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol. 1997;92(4):586-91.
37. Falk GW, Rice TW, Goldblum JR, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49(2):170-6.
38. Headrick JR, Nichols FC 3rd, Miller DL, et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann Thorac Surg. 2002;73(6):1697-702.
39. Tseng EE, Wu TT, Yeo CJ, et al. Barrett's esophagus with high grade dysplasia: surgical results and long-term outcome-an update. J Gastrointest Surg. 2003;7(2):164-70.
40. Sujendran V, Sica G, Warren B, et al. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus. Eur J Cardiothorac Surg. 2005;28(5):763-6.
41. Reed MF, Tolis G Jr, Edil BH, et al. Surgical treatment of esophageal high-grade dysplasia. Ann Thorac Surg. 2005;79(4):1110-5.
42. Wang VS, Hornick JL, Sepulveda JA, et al. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest Endosc. 2009;69(4):777-83.
43. Nasr JY, Schoen RE. Prevalence of adenocarcinoma at esophagectomy for Barrett's esophagus with high grade dysplasia. J Gastrointest Oncol. 2011;2(1):34-8.
44. Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol. 2008;6(2):159-64.
45. Tharavej C, Hagen JA, Peters JH, Portale G, Lipham J, DeMeester SR, et al. Predictive factors of coexisting cancer in Barrett's high-grade dysplasia. Surg Endosc. 2006;20(3):439-43.
46. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut. 1998;43(2):216-22.
47. Fountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg. 2004;91(8):997-1003.
48. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002;122(3):633-40.
49. Wong T, Tian J, Nagar AB. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am J Med. 2010;123(5):462-7.
50. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131(5):1392-9.
51. Singh R, Ragunath K, Jankowski J. Barrett's Esophagus: diagnosis, Screening, Surveillance, and Controversies. Gut Liver. 2007;1(2):93-100.
52. Vieth M, Ell C, Gossner L, May A, Stolte M. Histological analysis of endoscopic resection specimens from 326 patients with Barrett's esophagus and early neoplasia. Endoscopy. 2004;36(9):776-81.
53. Dunbar KB, Canto MI. Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc. 2010;72(3):668.
54. Qiu L, Pleskow DK, Chuttani R, et al. Multispectral scanning during endoscopy guides biopsy of dysplasia in Barrett's esophagus. Nat Med. 2010;16(5):603-6.
55. Kara MA, Smits ME, Rosmolen D, et al. A randomized crossover study comparing light-induced fluorescence endoscopy with standard videoendoscopy for the detection of early neoplasia in Barrett's esophagus. Gastrointest Endosc. 2005;61(6):671-8.
56. Curvers W, Baak L, Kiesslich R, et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus. Gastroenterology. 2008;134(3):670-9.
57. Thomas T, Singh R, Ragunath K. Trimodal imaging-assisted endoscopic mucosal resection of early Barrett's neoplasia. Surg Endosc. 2009;23(7):1609-13.
58. Odze RD, Lauwers GY. Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy. Endoscopy. 2008;40(12):1008-15.
59. Liu L, Hofstetter WL, Rashid A, et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol. 2005;29:1079-85.
60. Badreddine RJ, Prasad GA, Lewis JT, et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin. Gastroenterol Hepatol. 2010;8(3):248-53.
61. Manner H, May A, Pech O, et al. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103(10):2589-97.
62. Curvers WL, Bansal A, Sharma P, et al. Endoscopic work-up of early Barrett's neoplasia. Endoscopy. 2008;40(12):1000-7.
63. A Report of the Working Party of the British Society of Gastroenterology, principal authors: A Watson, RC Heading, NA Shepherd. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. 2005.
64. Chennat J, Waxman I. Endoscopic treatment of Barrett's esophagus: from metaplasia to intramucosal carcinoma. World J Gastroenterol. 2010;16(30):3780-5.
65. Leung WD, Chennat J. Comparison of endoscopic and surgical resection of intramucosal carcinoma in Barrett's esophagus. Expert Rev Gastroenterol Hepatol. 2011;5(5):575-8.
66. Nealis TB, Washington K, Keswani RN. Endoscopic therapy of esophageal premalignancy and early malignancy. J Natl Compr Canc Netw. 2011;9(8):890-9.
67. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology. 2009;137(3):815-23.
68. Schembre DB, Huang JL, Lin OS, et al. Treatment of Barrett's esophagus with early neoplasia: a comparison of endoscopic therapy and esophagectomy. Gastrointest Endosc. 2008;67(4):595-601.
69. Singh S, Sharma P. How effective is endoscopic therapy in the treatment of patients with early esophageal cancer? Nat Clin Pract Gastroenterol Hepatol. 2009;6(2):70-1.
70. Das A, Singh V, Fleischer DE, et al. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008;103(6):1340-5.
71. Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;50(5):106-12.
72. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2007;132(4):1226-33.
73. Bennett C, Green S, Barr H, et al. Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. Cochrane Database Syst Rev. 2010;12(5):CD007334.
74. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology. 2011;141(2):460-8.
75. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360(22):2277-88.
76. Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010;8(1):23-9.
77. Badreddine RJ, Prasad GA, Wang KK, et al. Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc. 2010;71(4):697-703.
78. Pech O, May A, Rabenstein T, Ell C. Endoscopic resection of early oesophageal cancer. Gut. 2007;56(11):1625-34.
79. Li YM, Li L, Yu CH, et al. A systematic review and meta-analysis of the treatment for Barrett's esophagus. Dig Dis Sci. 2008;53(11):2837-46.
80. Pech O, Behrens A, May A, Nachbar L, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008;57(9):1200-6.
81. van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett's oesophagus with high-grade dysplasia or early cancer: a multicentre randomised trial. Gut. 2011;60(6):765-73.
82. Hull MJ, Mino-Kenudson M, Nishioka NS, et al. Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol. 2006;30(1):114-8.
83. Moss A, Bourke MJ, Hourigan LF, et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol. 2010;105(6):1276-83.
84. ASGE Technology Committee, Kantsevoy SV, Adler DG, Conway JD, Diehl DL, Farraye FA, et al. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc. 2008;68(1):11-8.
85. Ciocirlan M, Lapalus MG, Hervieu V, et al. Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus. Endoscopy. 2007;39(1):24-9.
86. Inoue H, Fukami N, Yoshida T, et al. Endoscopic mucosal resection for esophageal and gastric cancers. J Gastroenterol Hepatol. 2002;17(4):382-8.
87. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007;66(3):460-8.
88. Ragunath K, Krasner N, Raman VS, et al. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol. 2005;40(7):750-8.
89. Biddlestone LR, Barham CP, Wilkinson SP, et al. The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol. 1998;22(2):239-45.
90. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62(4):488-98.
91. Bulsiewicz WJ, Shaheen NJ. The role of radiofrequency ablation in the management of Barrett's esophagus. Gastrointest Endosc Clin N Am. 2011;21(1):95-109.
92. Herrero LA, van Vilsteren FG, Pouw RE, et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett's esophagus longer than 10 cm. Gastrointest Endosc. 2011;49(5):286-301.
93. Lyday WD, Corbett FS, Kuperman DA, et al. Radiofrequency ablation of Barrett's esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy. 2010;42(4):272-8.
94. Semlitsch T, Jeitler K, Schoefl R, et al. A systematic review of the evidence for radiofrequency ablation for Barrett's esophagus. Surg Endosc. 2010;24(12):2935-43.
95. Sharma P, Wani S, Weston AP, Bansal A, et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut. 2006;55(9):1233-9.
96. Mino-Kenudson M, Ban S, Ohana M, et al. Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol. 2007;31(3):403-9.
97. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut. 2000;46(4):574-7.
98. Titi M, Overhiser A, Ulusarac O, et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. Gastroenterology. 2012;143(3):564-6.
99. Gray NA, Odze RD, Spechler SJ. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol. 2011;106(11):1899-908.
100. Fleischer DE, Overholt BF, Sharma PK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42(10):781-9.
101. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet. 2009;373(9666):850-61.
102. Lim CH, Rotimi O, Dexter SP, et al. Randomized crossover study that used methylene blue or random 4-quadrant biopsy for the diagnosis of dysplasia in Barrett's esophagus. Gastrointest Endosc. 2006;64(2):195-9.
103. Ragunath K, Krasner N, Raman VS, et al. A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus. Endoscopy. 2003;35(12):998-1003.
104. Pohl H, Rosch T, Vieth M, et al. Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut. 2008;57(12):1648-53.
105. Sharma P, Bansal A, Mathur S, et al. The utility of a novel narrow band imaging endoscopy system in patients with Barrett's esophagus. Gastrointest Endosc. 2006;64(2):167-75.
106. Curvers WL, Singh R, Song LM, et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut. 2008;57(2):167-72.
107. Niepsuj K, Niepsuj G, Cebula W, et al. Autofluorescence endoscopy for detection of high-grade dysplasia in short-segment Barrett's esophagus. Gastrointest Endosc. 2003;58(5):715-9.
108. Kara MA, Peters FP, Fockens P, et al. Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett's esophagus. Gastrointest Endosc. 2006;64(2):176-85.
109. Kara MA, Peters FP, Ten Kate FJ, et al. Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett's esophagus. Gastrointest Endosc. 2005;61(6):679-85.
110. Bird-Lieberman EL, Neves AA, Lao-Sirieix P, et al. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med. 2012;18:315-21.
111. The Esophageal Adenocarcinoma Genetics Consortium, The Wellcome Trust Case Control Consortium 2, Su Z, Gay LJ, Strange A, Palles C, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet. 2012; 44(10):1131-1136.
112. Gerson LB, Edson R, Lavori PW, et al. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96(7):2005-12.
113. Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc. 2003;58(5):661-70.
114. Kadri S, Lao-Sirieix P, Fitzgerald RC. Developing a nonendoscopic screening test for Barrett's esophagus. Biomark Med. 2011;5(3):397-404.
115. Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ. 2010;10(341):c4372.
116. Yoshinaga S, Gotoda T, Kusano C, et al. Clinical impact of endoscopic submucosal dissection for superficial adenocarcinoma located at the esophagogastric junction. Gastrointest Endosc. 2008;67:202-9.
117. Ono S, Fujishiro M, Niimi K, et al. Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc. 2009;70:860-6.
118. Koike T, Nakagawa K, Iijima K, et al. Endoscopic resection (endoscopic submucosal dissection/endoscopic mucosal resection) for superficial Barrett's esophageal cancer. Digestive Endoscopy. 2013;25(Suppl. 1):20-8.